Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-145 + Plerixafor for HSC Mobilization in Multiple Myeloma
NCT04552743Phase 2Completed
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MGTA-145 in multiple myeloma (MM). Primary endpoint: Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests at 2 days. Started Oct 2020; status: completed.
02
Drugs
MGTA-145
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04552743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552743.